Answers are grounded in this paper and cite their sources.
Review discusses conflicting outcomes of low molecular weight heparin for severe preeclampsia prevention in high-risk pregnant women, highlighting the need for trial standardization.
Low molecular weight heparin has been extensively evaluated for the prevention of preeclampsia in high-risk pregnant women; however, the results from these trials have been conflicting. This review discusses the potential mechanisms of action of low molecular weight heparin for the prevention of severe preeclampsia, how to optimize the selection of high-risk women for participation in future trials, and the importance of trial standardization.
No takes yet. Share an insight, caveat, or question.
McLaughlin et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: